ORIC Pharmaceuticals plans Phase 3 enozertinib trial in lung cancer for first half of 2027
Bitget2026/10/23 07:15- ORIC Pharmaceuticals plans to start Redwood-1, a global Phase 3 trial of enozertinib in first-line EGFR atypical lung cancer, in first-half 2027.
- Phase 1b results presented at ESMO Congress 2026 showed tumor shrinkage, including brain metastases, with some brain tumors disappearing completely.
- Treatment-related side effects caused no discontinuations; survival and response-duration findings remain immature.
- The planned trial will enroll approximately 360 patients, comparing enozertinib with physician-selected osimertinib or afatinib.
- Response results could support accelerated approval, while progression-free survival will underpin the full-approval assessment.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Blackstone (BX.US) injects up to $1.5 billion, providing fresh ammunition for Pfizer (PFE.US) in the weight-loss drug race
Pfizer announced on Wednesday that it has reached an agreement with Blackstone to obtain up to $1.5 billions in funding to support the development of its experimental monthly obesity treatment drug.
Bernstein Downgrades Nvidia Rating and Target Price
Google (GOOGL.US) DeepMind launches AlphaGenome 2: Capable of decoding DNA cells with nearly double the mutation identification capacity
Google DeepMind has released its AI model AlphaGenome 2, which is trained on maps of over 100 millions of cells and has nearly double the ability of its predecessor in identifying gene expression variations.
The White House did not intervene in the decision-making of Nvidia's board of directors.
Crypto prices
More
